These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 26239914)

  • 1. Cell therapy for Parkinson's disease: Functional role of the host immune response on survival and differentiation of dopaminergic neuroblasts.
    Wenker SD; Leal MC; Farías MI; Zeng X; Pitossi FJ
    Brain Res; 2016 May; 1638(Pt A):15-29. PubMed ID: 26239914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
    Chen W; Huang Q; Ma S; Li M
    ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons.
    Sundberg M; Bogetofte H; Lawson T; Jansson J; Smith G; Astradsson A; Moore M; Osborn T; Cooper O; Spealman R; Hallett P; Isacson O
    Stem Cells; 2013 Aug; 31(8):1548-62. PubMed ID: 23666606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.
    Levy YS; Stroomza M; Melamed E; Offen D
    J Mol Neurosci; 2004; 24(3):353-86. PubMed ID: 15655260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of Parkinson's disease pathophysiology for the development of cell replacement strategies and drug discovery in neurodegenerative diseases.
    Pan-Montojo F; Funk RH
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):907-20. PubMed ID: 23131153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Han F; Wang W; Chen B; Chen C; Li S; Lu X; Duan J; Zhang Y; Zhang YA; Guo W; Li G
    Cytotherapy; 2015 May; 17(5):665-79. PubMed ID: 25747741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival and engraftment of dopaminergic neurons manufactured by a Good Manufacturing Practice-compatible process.
    Peng J; Liu Q; Rao MS; Zeng X
    Cytotherapy; 2014 Sep; 16(9):1305-12. PubMed ID: 25065637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Embryonic stem cell-derived L1 overexpressing neural aggregates enhance recovery in Parkinsonian mice.
    Cui YF; Hargus G; Xu JC; Schmid JS; Shen YQ; Glatzel M; Schachner M; Bernreuther C
    Brain; 2010 Jan; 133(Pt 1):189-204. PubMed ID: 19995872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical translation of stem cell transplantation in Parkinson's disease.
    Lindvall O
    J Intern Med; 2016 Jan; 279(1):30-40. PubMed ID: 26332959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating Wnt signaling to improve cell replacement therapy for Parkinson's disease.
    Parish CL; Thompson LH
    J Mol Cell Biol; 2014 Feb; 6(1):54-63. PubMed ID: 24334258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced pluripotent stem cell-based studies of Parkinson's disease: challenges and promises.
    Sanchez-Danes A; Benzoni P; Memo M; Dell'Era P; Raya A; Consiglio A
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1114-27. PubMed ID: 24040813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells.
    Clark BJ; Lelos MJ; Loring JF
    Stem Cells; 2024 Sep; 42(9):781-790. PubMed ID: 38902932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular manipulation targeting regulation of dopaminergic differentiation and proliferation of neural stem cells or pluripotent stem cells.
    Ding YX; Wei LC; Wang YZ; Cao R; Wang X; Chen LW
    CNS Neurol Disord Drug Targets; 2011 Jun; 10(4):517-28. PubMed ID: 21495963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards stem cell based therapies for Parkinson's disease.
    Parmar M
    Development; 2018 Jan; 145(1):. PubMed ID: 29311261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacing what's lost: a new era of stem cell therapy for Parkinson's disease.
    Fan Y; Winanto ; Ng SY
    Transl Neurodegener; 2020; 9():2. PubMed ID: 31911835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiation and Characterization of Dopaminergic Neurons From Baboon Induced Pluripotent Stem Cells.
    Grow DA; Simmons DV; Gomez JA; Wanat MJ; McCarrey JR; Paladini CA; Navara CS
    Stem Cells Transl Med; 2016 Sep; 5(9):1133-44. PubMed ID: 27343168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-based therapies for Parkinson's disease.
    Dyson SC; Barker RA
    Expert Rev Neurother; 2011 Jun; 11(6):831-44. PubMed ID: 21651331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated astrocytes enhance the dopaminergic differentiation of stem cells and promote brain repair through bFGF.
    Yang F; Liu Y; Tu J; Wan J; Zhang J; Wu B; Chen S; Zhou J; Mu Y; Wang L
    Nat Commun; 2014 Dec; 5():5627. PubMed ID: 25517983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell therapy for Parkinson's disease is coming of age: current challenges and future prospects with a focus on immunomodulation.
    Wenker SD; Pitossi FJ
    Gene Ther; 2020 Feb; 27(1-2):6-14. PubMed ID: 30992523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.
    Chen LW; Kuang F; Wei LC; Ding YX; Yung KK; Chan YS
    CNS Neurol Disord Drug Targets; 2011 Jun; 10(4):449-58. PubMed ID: 21495962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.